Memantin Pharmas (Memantine Hydrochloride)

Memantin Pharmas (memantine) acts on the glutamatergic pathway to manage cognitive decline in dementia.

• Alzheimer’s disease (moderate to severe): helps improve cognition, daily functioning, and overall clinical status in affected patients.
• Alzheimer’s disease (mild to moderate): may provide modest benefits in cognition and behavior when used in combination with other therapies.
• Vascular dementia (off‑label): sometimes considered for symptomatic relief of cognitive symptoms, though not an approved indication.

• Memantine is a non‑competitive antagonist of the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx caused by overstimulation, thereby limiting excitotoxic neuronal injury and supporting neuronal survival in the brain.

Memantin Pharmas may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness or low energy.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Hallucinations: visual or auditory disturbances.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms.
• Liver injury: elevated liver enzymes or hepatitis.

When prescribing Memantin Pharmas, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: use with caution in patients with liver disease.
• History of seizures: monitor closely for increased seizure activity.
• Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity.
• Psychiatric symptoms: watch for worsening confusion or agitation.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantin Pharmas can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Other NMDA antagonists (e.g., amantadine): may increase neurotoxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise memantine plasma levels.
• Drugs that lower seizure threshold (e.g., bupropion): may heighten seizure risk.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of edema.
• Antihypertensives: possible additive hypotensive effect.
• Anticholinergics: may exacerbate cognitive impairment.